ESC 2026: ESC 2026: Head-to-head study compares inclisiran and bempedoic acid

Inclisiran outperformed bempedoic acid in LDL-C lowering and target attainment, supporting differentiation in high-risk patients. Inclisiran outperformed bempedoic acid in LDL-C lowering and target attainment, supporting differentiation in high-risk patients. Inclisiran and bempedoic acid are established treatments for dyslipidaemia that lower LDL-C through distinct mechanisms. Image credit: [fizkes]/Shutterstock.com Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can: Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise. Hard data and…

Source: Clinical Trials Arena